Quantum-Si incorporated
NASDAQ:QSIBiotechnology
+$0.05 today
- Market cap
- $201.80M
- Beta
- 3.17
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.48
Volume 5.35M
Average 5.64M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Quantum-Si incorporated
NASDAQ:QSI
Intrinsic Alpha fair value
Locked
Current Price
$1.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +112.6% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +112.6% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | $1.39B | $43.01 | Not rated | -21.4 | +153.14% |
Solid Biosciences Inc. NASDAQ:SLDB | $763.42M | $6.84 | Not rated | -4.3 | +39.37% |
Aura Biosciences, Inc. NASDAQ:AURA | $739.97M | $7.11 | Not rated | -3.7 | +32.16% |
Annexon, Inc. NASDAQ:ANNX | $642.26M | $3.92 | Not rated | -4.8 | +8.44% |
Altimmune, Inc. NASDAQ:ALT | $319.98M | $1.65 | Not rated | -3.7 | -67.10% |
Autolus Therapeutics plc NASDAQ:AUTL | $311.41M | $1.17 | Not rated | -1.4 | -15.50% |
DBV Technologies S.A. NASDAQ:DBVT | $263.50M | $11.02 | Not rated | -8.3 | -28.28% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $252.48M | $2.30 | Not rated | -1.7 | -28.23% |
ADC Therapeutics S.A. NYSE:ADCT | $171.07M | $1.34 | Not rated | -1.2 | -66.25% |
enGene Holdings Inc. NASDAQ:ENGN | $161.51M | $2.41 | Not rated | -1.8 | -75.00% |
Continue the stock analysis
Jump to another research area for this company.